Processing

Please wait...

Settings

Settings

1. WO1996005827 - N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES

Publication Number WO/1996/005827
Publication Date 29.02.1996
International Application No. PCT/US1995/010501
International Filing Date 17.08.1995
Chapter 2 Demand Filed 01.03.1996
IPC
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/5513 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 243/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
243Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
06having the nitrogen atoms in positions 1 and 4
10condensed with carbocyclic rings or ring systems
141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
16substituted in position 5 by aryl radicals
18substituted in position 2 by nitrogen, oxygen or sulfur atoms
24Oxygen atoms
CPC
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/5513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogen atoms, e.g. dilazep
55131,4-Benzodiazepines, e.g. diazepam ; or clozapine
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 243/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
243Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
06having the nitrogen atoms in positions 1,4
10condensed with carbocyclic rings or ring systems
141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
16substituted in position 5 by aryl radicals
18substituted in position 2 by nitrogen, oxygen or sulfur atoms
24Oxygen atoms
Applicants
  • MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065, US (AllExceptUS)
  • CLAREMON, David, A. [US/US]; US (UsOnly)
  • LIVERTON, Nigel [GB/US]; US (UsOnly)
  • SELNICK, Harold, G. [US/US]; US (UsOnly)
Inventors
  • CLAREMON, David, A.; US
  • LIVERTON, Nigel; US
  • SELNICK, Harold, G.; US
Common Representative
  • MERCK & CO., INC.; 126 East Lincoln Avenue Rahway, NJ 07065, US
Priority Data
292,44918.08.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES
(FR) N-2,3-DIHYDRO-1-(2-PROPYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES
Abstract
(EN)
This invention is concerned with novel compounds represented by structural formula (I), where R1 is formula (II) or (III); X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl; n is 0, 1 or 2; and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy; as the racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers, and pharmaceutically acceptable crystal forms, salts, or hydrates thereof.
(FR)
Cette invention concerne de nouveaux composés représentés par la formule développée (I). Dans cette formule, R1 correspond à la formule (II) ou (III); X et Y sont chacun indépendamment un hydrogène, un fluoro, un chloro, un bromo, un iodo ou un trifluorométhyle; et n représente 0, 1 ou 2; et R2 est un hydrogène, un fluoro, un chloro, un bromo, un iodo, un trifluorométhyle, un méthyle ou un méthoxy. L'invention concerne également les racémates, les mélanges d'énantiomères, les diastéréoisomères individuels, les énantiomères individuels et leurs formes cristallines, leurs sels ou leurs hydrates acceptables sur le plan pharmaceutique.
Latest bibliographic data on file with the International Bureau